Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRN-1201 + Pembrolizumab in Metastatic NSCLC
NCT03417882Phase 2Terminated
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.
- Start
- Jan 2019
- Primary completion
- Dec 2022
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of grn-1201 in non-small cell lung cancer (NSCLC), sponsored by BrightPath Biotherapeutics Co., Ltd.. Started Jan 2019; status: terminated.
02
Drugs
grn-1201
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03417882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417882.